MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
HURA — TuHURA Biosciences, Inc. Common Stock
NasdaqTuHURA Biosciences, Inc. Common Stock
$1.87
-0.04(-2.09%)
- O
- 1.94
- H
- 1.94
- L
- 1.85
- V
- 333.98K
⏱️ End-of-day dataAs of Oct 5, 2026
HURA — Latest News & Headlines
6 StoriesA cancer patent also covers cell-based treatments, not just antibody-linked drugs - Stock Titan
A cancer patent also covers cell-based treatments, not just antibody-linked drugs Stock Titan
Oracle gave Larry Ellison and his co-CEOs nearly $1 billion in stock options. By fiscal year end, all were underwater - fortune.com
Oracle gave Larry Ellison and his co-CEOs nearly $1 billion in stock options. By fiscal year end, all were underwater fortune.com
Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress - Investing.com UK
Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress Investing.com UK
Oracle (NYSE: ORCL) executive Mark Hura has 8,456 and 20,805 shares withheld for taxes. - Stock Titan
Oracle (NYSE: ORCL) executive Mark Hura has 8,456 and 20,805 shares withheld for taxes. Stock Titan
TuHURA Biosciences receives U.S. patent for DOR technology By Investing.com - Investing.com Canada
TuHURA Biosciences receives U.S. patent for DOR technology By Investing.com Investing.com Canada
TuHURA Biosciences Draws Additional Funds From Credit Facility - TipRanks
TuHURA Biosciences Draws Additional Funds From Credit Facility TipRanks